Toni Choueiri, MD· @DrChoueiri · X·· 1 day agoScore70
Body
Promising data presented by @AndreaNecchi at #ESMO26 #GDFather-NEO.
Nivo + Visugromab
• Higher response (pCR and ORR)
• At median F/U 15.7 mo: no recurrence observed after pCR
• No new safety signal
Paper out in @NatureMedicine. Congrats Andrea and co-authors !
@myESMO @OncoAlert
54 views · 1 like · 1 repost · 0 replies
Conference abstracts
4757ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial
Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgSource: Toni Choueiri, MD · x.com